- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| 08.09. | OSE Immunotherapeutics - executive interview | 289 | In this interview, Silvia Comis MD, chief clinical and medical research officer at OSE Immunotherapeutics, covers the company's lead immuno-oncology candidate, Tedopi. She outlines the current unmet... ► Artikel lesen | ||
| 05.09. | The Biotech Growth Trust - Encouraging recent performance | 366 | The Biotech Growth Trust (BIOG) is managed Geoff Hsu and Josh Golomb at leading global healthcare specialist OrbiMed. The trust provides access to the rapidly evolving biotech sector, seeking long-term... ► Artikel lesen | ||
| 04.09. | The Schiehallion Fund - Shooting for the stars | 363 | The Schiehallion Fund (MNTN) invests in later-stage private companies with the potential for transformational growth and eventual public listing. The fund owns some of the world's most exciting, game-changing... ► Artikel lesen | ||
| 04.09. | Amoeba - Ready to launch | 459 | Amoéba is ready to launch its innovative and patented WmCM amoeba lysate active ingredient into the vast crop protection and anti-ageing skincare cosmetics markets. Excellent field trial results, combined... ► Artikel lesen | ||
| 04.09. | Intralot - Contract wins and transformational M&A | 403 | Intralot reported 'steady' 1-2% growth in revenue and EBITDA in H125, with underlying growth dampened by foreign currency translation, and trends quite variable between the quarters. From a contract... ► Artikel lesen | ||
| 03.09. | DUG Technology - Awarded material software contract | 358 | DUG Technology has been awarded a significant contract with Petronas to provide software and HPCaaS services for a minimum three-year term. After paying a managed services partner to undertake part... ► Artikel lesen | ||
| 03.09. | Halyk Bank - Strong year-on-year earnings growth in Q225 | 595 | Halyk Bank delivered a strong 26.1% y-o-y increase in net profit to KZT253.6bn in Q225, leading to a healthy annualised return on equity (ROE) of 32.2% (up from 31.7% in Q224). Loan book growth moderated... ► Artikel lesen | ||
| 03.09. | Hansa Investment Company - Streamlined for success | 322 | Hansa Investment Company (HICL) offers investors a portfolio of best-in-class managers that are often hard to access for retail investors, including country and thematic funds, a portfolio of direct... ► Artikel lesen | ||
| 02.09. | Team Internet Group - Transitional H1, expecting the benefits in H2 | 365 | Team Internet's H1 results reflect transitions in all three of its divisions, which should start to come through in an improved mix and margins from H2. Strong customer wins in DIS, international expansion... ► Artikel lesen | ||
| 02.09. | everplay group - H125 shows resilience while markets recover | 351 | Raising guidance (however modest the amount) during a CEO interregnum is not a common occurrence. It is testament not only to the strength of everplay group's current management team, but also to the... ► Artikel lesen | ||
| 01.09. | Zalaris - Solid progress in Q225 | 366 | Zalaris made solid progress in Q225, with revenue up 12% y-o-y and the adjusted EBIT margin expanding 3.3pp to 12.1%. Managed Services continues to win new customers and expand work with existing customers... ► Artikel lesen | ||
| 01.09. | Altron - Mixed performance in H126 | 410 | For H126, Altron has seen the benefit of a diversified portfolio in a challenging market environment. The IT Services business has suffered from constrained IT budgets and price pressure, with an operating... ► Artikel lesen | ||
| 01.09. | CLIQ Digital - Pressing the pause button | 993 | CLIQ Digital no longer intends to delist or to carry out a partial share buyback, and has withdrawn current year financial guidance. This uncertainty stems from policy changes by the group's payment... ► Artikel lesen | ||
| 01.09. | Basilea Pharmaceutica - Gearing up for the next growth phase | 483 | Basilea's H125 results reflected strong sales traction, with revenues up 36.3% y-o-y to CHF104m, underpinned by 21.7% growth in royalties. A key strategic milestone was the US launch of Zevtera, diversifying... ► Artikel lesen | ||
| 29.08. | OSE Immunotherapeutics - Spotlight on OSE's diverse clinical pipeline | 386 | OSE Immunotherapeutics has made tangible progress across its clinical development pipeline, creating positive momentum, in our view. In immuno-inflammation, monoclonal antibody therapy lusvertikimab... ► Artikel lesen | ||
| 28.08. | Filtronic - Record order from SpaceX | 445 | Hot on the heels of a $32.5m/£24.0m order in June, SpaceX has just placed a $62.5m/£47.3m order, the highest yet. This is for E-band solid-state power amplifiers (SSPAs) manufactured using gallium nitride... ► Artikel lesen | ||
| 28.08. | Nabaltec - Subdued H125 despite strong structural growth | 929 | Nabaltec recorded subdued results in H125, due to an increasingly challenging market environment, with both revenue and EBIT decreasing 1.7% and 18.5% y-o-y, respectively, to €106.5m and €8.9m. Despite... ► Artikel lesen | ||
| 28.08. | Murray International Trust - Delivering what it says on the tin | 292 | Murray International Trust's (MYI's) co-managers, Martin Connaghan and Samantha Fitzpatrick at Aberdeen Group, are encouraged by the trust's H125 results. During this volatile period in global markets... ► Artikel lesen | ||
| 28.08. | Alzinova - Innovative new approach to Alzheimer's | 396 | Alzinova is a Sweden-based clinical-stage biopharmaceutical company seeking to advance treatments for Alzheimer's disease (AD) via protein modification and immunotherapy-based solutions. Alzinova's... ► Artikel lesen | ||
| 27.08. | DUG Technology - Significant boost to order intake in H225 | 357 | DUG Technology's FY25 results confirmed that order intake stepped up in H225, with intake of $45.7m 131% higher half-on-half, resulting in a record order book of $52m at the end of the year. While revenue... ► Artikel lesen | ||
| 27.08. | Topps Tiles - Laying the groundwork for higher growth | 363 | Topps Tiles' (TPT's) diversification into larger addressable markets with more trading brands means it is well-placed to service more products to more customers in more sectors, and with greater efficiency... ► Artikel lesen | ||
| 27.08. | Oncopeptides - Targeted oncology with commercial momentum | 369 | Oncopeptides (ONCO) is a Swedish biotech that aims to develop and commercialise therapies for difficult-to-treat cancers, with a focus on haematological diseases. Its lead product, Pepaxti, was approved... ► Artikel lesen | ||
| 26.08. | Oryzon Genomics - Foray into sickle cell disease | 375 | Oryzon Genomics has announced that the European Medicines Agency (EMA) has provided regulatory clearance for a Phase Ib trial of iadademstat in sickle cell disease. The Phase Ib study (named RESTORE)... ► Artikel lesen | ||
| 26.08. | ProCredit Holding - More cautious amid macroeconomic uncertainty | 972 | ProCredit Holding (PCB) continues to make good progress in building the scale of its loan book, with 7.2% growth in H125 at constant currency (on track to meet management's FY25 guidance of c 12%).... ► Artikel lesen | ||
| 26.08. | The Platform Group - Robust revenue growth and margin delivery | 489 | The Platform Group (TPG) delivered robust growth in H125 as it continues to benefit from a greater presence in more verticals, with more partners (+26% y-o-y) and ultimately serving more customers (+29%).... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .